At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 28 enrolled
Drug / intervention
Experimental: B244drug
Likely dose
Experimental: B244 30mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Multicenter, Phase Ib Study of B244 Delivered as a Topical Spray to Assess Safety in Pediatric Subjects Aged 2 to 17 Years With Atopic Dermatitis
In Brief
A Phase 1 clinical trial evaluating Experimental: B244 for Eczema and Atopic Dermatitis. Completed, enrolled 28 participants across 6 sites.
Detailed Summary
An open-label, multicenter, Phase Ib study of B244 delivered as a topical spray to assess safety in pediatric subjects aged 2 to 17 years with atopic dermatitis Condition or disease Intervention/treatment Phase Atopic Dermatitis (Eczema) Biological: B244 Phase 1b
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEczema, Atopic Dermatitis
CountriesUnited States
CollaboratorsNovella Clinical
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
Enrollment StartDec 2018
First PostedDec 2018
Primary CompletionMay 2019
Study CompletionJun 2019
TodayJul 2026
First PostedDec 14, 2018
Enrollment StartDec 7, 2018
Primary CompletionMay 18, 2019
Study CompletionJun 10, 2019
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 7.5 years ago
Interventions
Experimental: B244drug
B244 suspension in 30ml/bottle